Cargando…

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?

Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Megna, Matteo, Ocampo-Garza, Sonia Sofia, Potestio, Luca, Fontanella, Giuseppina, Gallo, Lucia, Cacciapuoti, Sara, Ruggiero, Angelo, Fabbrocini, Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533054/ https://www.ncbi.nlm.nih.gov/pubmed/34680599 http://dx.doi.org/10.3390/biomedicines9101482

Ejemplares similares

Towards Personalized Medicine in Psoriasis: Current Progress
por: Camela, Elisa, et al.
Publicado: (2022)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued?
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis
por: Ruggiero, Angelo, et al.
Publicado: (2021)

Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series()
por: Megna, Matteo, et al.
Publicado: (2022)

A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab
por: Megna, Matteo, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2022)

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
por: Ruggiero, Angelo, et al.
Publicado: (2022)

A case of erythrodermic psoriasis successfully treated with apremilast
por: Megna, Matteo, et al.
Publicado: (2021)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
por: Potestio, Luca, et al.
Publicado: (2023)

Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
por: Megna, Matteo, et al.
Publicado: (2022)

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
por: Megna, Matteo, et al.
Publicado: (2022)

JAK Inhibitors in Psoriatic Disease
por: Megna, Matteo, et al.
Publicado: (2023)

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge
por: Potestio, Luca, et al.
Publicado: (2023)

Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire
por: Camela, Elisa, et al.
Publicado: (2023)

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
por: Megna, Matteo, et al.
Publicado: (2021)

Adalimumab biosimilar in a pediatric patient: Clinical and in vivo reflectance confocal microscopy evaluation
por: Megna, Matteo, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2023)

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
por: Megna, Matteo, et al.
Publicado: (2023)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
por: Potestio, Luca, et al.
Publicado: (2023)

Ixekizumab in scalp psoriasis: Clinical, dermoscopical, and in vivo reflectance confocal microscopy evaluation
por: Ocampo‐Garza, Sonia Sofia, et al.
Publicado: (2022)

A Case of Adult-onset Facial Cutaneous Mastocytoma: Clinical and Dermoscopic Findings
por: Megna, Matteo, et al.
Publicado: (2022)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
por: Potestio, Luca, et al.
Publicado: (2023)

New‐onset lichen planus arising after COVID‐19 vaccination
por: Zagaria, Orlando, et al.
Publicado: (2022)

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
por: Potestio, Luca, et al.
Publicado: (2023)

Letter to the editor regarding article “Yalici‐Armagan B, Tabak GH, Dogan‐Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID‐19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1–5”
por: Potestio, Luca, et al.
Publicado: (2021)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study
por: Megna, Matteo, et al.
Publicado: (2023)

Letter to the editor regarding the article “Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID‐19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610.”
por: Potestio, Luca, et al.
Publicado: (2022)

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
por: Ruggiero, A., et al.
Publicado: (2021)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

A case of linear psoriasis in a young patient with Down syndrome and review of the literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
por: Megna, Matteo, et al.
Publicado: (2023)

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
por: Megna, Matteo, et al.
Publicado: (2022)

Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19
por: Martora, Fabrizio, et al.
Publicado: (2023)

A Case of Ofuji Disease Successfully Treated with the Combination of Low-Dose Indomethacin and Topical Tacrolimus
por: Marasca, Claudio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p3fsc0tfdknpqudenobgrij4ru